Nabil F. Saba
#59,124
Most Influential Person Now
Oncologist
Nabil F. Saba's AcademicInfluence.com Rankings
Nabil F. Sabamedical Degrees
Medical
#1425
World Rank
#1762
Historical Rank
Hematology
#38
World Rank
#44
Historical Rank
Oncology
#173
World Rank
#179
Historical Rank
Nabil F. Sabaphilosophy Degrees
Philosophy
#10421
World Rank
#14278
Historical Rank
Logic
#7294
World Rank
#9010
Historical Rank
Download Badge
Medical Philosophy
Why Is Nabil F. Saba Influential?
(Suggest an Edit or Addition)According to Wikipedia, Nabil F. Saba is an American oncologist. He is currently Professor and Vice-chair of Hematology and Medical Oncology, and Professor of Otolaryngology at the Winship Cancer Institute at the Emory University School of Medicine in Atlanta, Georgia. He is a specialist in the field of head and neck oncology. Saba has authored more than 200 peer-reviewed articles. He is the inaugural Lynne and Howard Halpern Chair in Head and Neck Cancer Research.
Nabil F. Saba's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. (2016) (1900)
- Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes. (2003) (552)
- Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. (2018) (477)
- Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study. (2017) (457)
- An update on larynx cancer (2017) (395)
- Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. (2017) (276)
- Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1–Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial (2019) (189)
- Adenoid cystic carcinoma of the head and neck (2012) (184)
- Paranasal sinus squamous cell carcinoma incidence and survival based on Surveillance, Epidemiology, and End Results data, 1973 to 2009 (2013) (157)
- Targeting the Epidermal Growth Factor Receptor (2006) (155)
- Management of locally recurrent nasopharyngeal carcinoma. (2019) (140)
- Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: A systematic review (2016) (132)
- Gender and Ethnic Disparities in Incidence and Survival of Squamous Cell Carcinoma of the Oral Tongue, Base of Tongue, and Tonsils: A Surveillance, Epidemiology and End Results Program-Based Analysis (2011) (110)
- High treatment-related mortality in cardiac amyloid patients undergoing autologous stem cell transplant (1999) (97)
- Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use (2019) (95)
- ACR appropriateness criteria retreatment of recurrent head and neck cancer after prior definitive radiation expert panel on radiation oncology-head and neck cancer. (2011) (93)
- The role of systemic therapy in the management of sinonasal cancer: A critical review. (2015) (84)
- Defining HPV-specific B cell responses in patients with head and neck cancer (2020) (83)
- Accuracy of computed tomography for predicting pathologic nodal extracapsular extension in patients with head-and-neck cancer undergoing initial surgical resection. (2014) (83)
- Comparison of Concurrent Use of Thoracic Radiation With Either Carboplatin-Paclitaxel or Cisplatin-Etoposide for Patients With Stage III Non–Small-Cell Lung Cancer: A Systematic Review (2017) (81)
- Nasal juvenile angiofibroma: Current perspectives with emphasis on management (2017) (79)
- Functional HPV-specific PD-1+ stem-like CD8 T cells in head and neck cancer (2021) (77)
- Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial. (2019) (77)
- Distinctive E‐cadherin and epidermal growth factor receptor expression in metastatic and nonmetastatic head and neck squamous cell carcinoma (2008) (76)
- The Current Role of Salvage Surgery in Recurrent Head and Neck Squamous Cell Carcinoma (2018) (74)
- Patient-derived xenografts faithfully replicated clinical outcome in a phase II co-clinical trial of arsenic trioxide in relapsed small cell lung cancer (2016) (72)
- MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation. (2018) (72)
- Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311) (2021) (72)
- Transoral robotic surgical resection followed by randomization to low- or standard-dose IMRT in resectable p16+ locally advanced oropharynx cancer: A trial of the ECOG-ACRIN Cancer Research Group (E3311). (2020) (69)
- Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck: The Active8 Randomized Clinical Trial (2018) (68)
- Risk Factors for Rising Incidence of Esophageal and Gastric Cardia Adenocarcinoma (2013) (66)
- Advances in Targeting HER3 as an Anticancer Therapy (2012) (65)
- Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors. (2016) (65)
- Lymph node ratio influence on risk of head and neck cancer locoregional recurrence after initial surgical resection: Implications for adjuvant therapy (2015) (64)
- CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer. (2018) (63)
- Head and neck cancer (2021) (63)
- Fatigue is associated with inflammation in patients with head and neck cancer before and after intensity-modulated radiation therapy (2016) (62)
- A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma (2015) (61)
- An update on the immune landscape in lung and head and neck cancers (2020) (60)
- HPV Positive Squamous Cell Carcinoma of the Oropharynx. Are we Observing an Unusual Pattern of Metastases? (2012) (59)
- A Review of Photodynamic Therapy for Neoplasms of the Head and Neck (2018) (57)
- Atypical Carcinoid Tumor of the Lung: A Surveillance, Epidemiology, and End Results Database Analysis (2015) (56)
- Nivolumab treatment beyond RECIST‐defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial (2019) (56)
- Chemoprevention of Head and Neck Cancer with Celecoxib and Erlotinib: Results of a Phase Ib and Pharmacokinetic Study (2013) (55)
- Examining expression of folate receptor in squamous cell carcinoma of the head and neck as a target for a novel nanotherapeutic drug (2009) (55)
- Role of Cyclooxygenase-2 in Tumor Progression and Survival of Head and Neck Squamous Cell Carcinoma (2009) (54)
- Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations (2021) (53)
- Chemoprevention of Head and Neck Cancer by Simultaneous Blocking of Epidermal Growth Factor Receptor and Cyclooxygenase-2 Signaling Pathways: Preclinical and Clinical Studies (2013) (53)
- Combination of Anti-HER3 Antibody MM-121/SAR256212 and Cetuximab Inhibits Tumor Growth in Preclinical Models of Head and Neck Squamous Cell Carcinoma (2014) (52)
- Pulmonary Sarcomatoid Carcinoma: An Analysis of the National Cancer Data Base (2017) (51)
- Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer. (2019) (50)
- Head and Neck Cancer: A Review of the Impact of Treatment Delay on Outcome (2018) (49)
- Racial disparities in squamous cell carcinoma of the oral tongue among women: a SEER data analysis. (2015) (49)
- Phase 1 and pharmacokinetic study of everolimus in combination with cetuximab and carboplatin for recurrent/metastatic squamous cell carcinoma of the head and neck (2014) (49)
- Oral Cavity Cancer: Risk Factors, Pathology, and Management (2015) (48)
- Comparison of quantum dot technology with conventional immunohistochemistry in examining aldehyde dehydrogenase 1A1 as a potential biomarker for lymph node metastasis of head and neck cancer. (2012) (47)
- HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models (2016) (47)
- Trends, predictors, and impact of systemic chemotherapy in small cell lung cancer patients between 1985 and 2005 (2016) (41)
- Abstract CT099: Nivolumab (nivo) vs investigator's choice (IC) for recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): CheckMate-141 (2016) (41)
- ACR appropriateness criteria® adjuvant therapy for resected squamous cell carcinoma of the head and neck. (2011) (40)
- Initial Performance of NI-RADS to Predict Residual or Recurrent Head and Neck Squamous Cell Carcinoma (2017) (39)
- Phase II Study of Docetaxel in Combination with Everolimus for Second- or Third-Line Therapy of Advanced Non–Small-Cell Lung Cancer (2013) (38)
- Heregulin and HER3 are prognostic biomarkers in oropharyngeal squamous cell carcinoma (2015) (37)
- Percutaneous feeding tubes in patients with head and neck cancer: rethinking prophylactic placement for patients undergoing chemoradiation. (2009) (37)
- Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer (2010) (37)
- ACR appropriateness criteria® ipsilateral radiation for squamous cell carcinoma of the tonsil (2012) (37)
- Concurrent chemoradiotherapy with or without surgery for patients with resectable esophageal cancer: An analysis of the National Cancer Data Base (2017) (35)
- Retinoids as chemoprevention for head and neck cancer: where do we go from here? (2005) (34)
- Real-world effectiveness of systemic agents approved for advanced non-small cell lung cancer: a SEER-Medicare analysis. (2013) (34)
- Acetylated Tubulin (AT) as a Prognostic Marker in Squamous Cell Carcinoma of the Head and Neck (2014) (34)
- Prevention of head and neck squamous cell carcinoma: removing the "chemo" from "chemoprevention". (2015) (33)
- Treatment allocation in patients with early‐stage esophageal adenocarcinoma: Prevalence and predictors of lymph node involvement (2016) (33)
- Targeted therapies in metastatic esophageal cancer: advances over the past decade. (2014) (33)
- Antiepidermal Growth Factor Receptor Therapy in Squamous Cell Carcinoma of the Head and Neck (2012) (33)
- 1043OTreatment beyond progression with nivolumab in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) in the phase 3 checkmate 141 study: A biomarker analysis and updated clinical outcomes (2017) (32)
- Toxicities of systemic agents in squamous cell carcinoma of the head and neck (SCCHN); A new perspective in the era of immunotherapy. (2017) (32)
- Do 18F-FDG PET/CT Parameters in Oropharyngeal and Oral Cavity Squamous Cell Carcinomas Indicate HPV Status? (2015) (32)
- Nivolumab versus investigator’s choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety in CheckMate 141 by age (2019) (32)
- Survival outcomes by high‐risk human papillomavirus status in nonoropharyngeal head and neck squamous cell carcinomas: A propensity‐scored analysis of the National Cancer Data Base (2019) (31)
- Mannitol to prevent cisplatin-induced nephrotoxicity in patients with squamous cell cancer of the head and neck (SCCHN) receiving concurrent therapy (2016) (31)
- Prognostic and predictive factors in recurrent and/or metastatic head and neck squamous cell carcinoma: A review of the literature. (2019) (31)
- Human papillomavirus 16 oncoprotein regulates the translocation of β‐catenin via the activation of epidermal growth factor receptor (2015) (29)
- A systematic review and recommendations on the use of plasma EBV DNA for nasopharyngeal carcinoma. (2021) (29)
- Bone marrow transplantation for nonmalignant diseases. (2002) (29)
- Heat shock protein 90 (HSP90) is overexpressed in p16-negative oropharyngeal squamous cell carcinoma, and its inhibition in vitro potentiates the effects of chemoradiation (2014) (29)
- Radiographic Imaging Does Not Reliably Predict Macroscopic Extranodal Extension in Human Papilloma Virus-Associated Oropharyngeal Cancer (2018) (28)
- Overview of autologous stem cell transplantation. (2000) (28)
- Organ preservation with chemoradiation in advanced laryngeal cancer: The problem of generalizing results from randomized controlled trials. (2017) (28)
- A phase 2 study of dalantercept, an activin receptor‐like kinase‐1 ligand trap, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (2016) (28)
- Association of Lymphovascular Space Invasion With Locoregional Failure and Survival in Patients With Node-Negative Oral Tongue Cancers (2017) (27)
- Nivolumab (Nivo) vs investigator’s choice (IC) in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Efficacy and safety in CheckMate 141 by prior cetuximab use. (2017) (26)
- Patterns of extralaryngeal spread of laryngeal cancer (2011) (26)
- Associations among human papillomavirus, inflammation, and fatigue in patients with head and neck cancer (2018) (25)
- Targeting the epidermal growth factor receptor. Trials in head and neck and lung cancer. (2006) (24)
- A Correlative Analysis of PD-L1, PD-1, PD-L2, EGFR, HER2, and HER3 Expression in Oropharyngeal Squamous Cell Carcinoma (2018) (24)
- Management of locally advanced HPV-related oropharyngeal squamous cell carcinoma: where are we? (2016) (24)
- A novel surgeon credentialing and quality assurance process using transoral surgery for oropharyngeal cancer in ECOG-ACRIN Cancer Research Group Trial E3311. (2020) (24)
- A Translational, Pharmacodynamic, and Pharmacokinetic Phase IB Clinical Study of Everolimus in Resectable Non–Small Cell Lung Cancer (2015) (24)
- Targeting HER (ERBB) signaling in head and neck cancer: An essential update. (2015) (23)
- Mutation and Transcriptional Profiling of Formalin-Fixed Paraffin Embedded Specimens as Companion Methods to Immunohistochemistry for Determining Therapeutic Targets in Oropharyngeal Squamous Cell Carcinoma (OPSCC): A Pilot of Proof of Principle (2015) (23)
- The Impact of Histologic Phenotype in the Treatment of Sinonasal Cancer (2017) (23)
- Predictors and outcomes of venous thromboembolism in hospitalized lung cancer patients: A Nationwide Inpatient Sample database analysis. (2015) (22)
- Perioperative Antibiotics in Clean-Contaminated Head and Neck Surgery: A Systematic Review and Meta-Analysis (2020) (22)
- Response assessment after induction chemotherapy for head and neck squamous cell carcinoma: From physical examination to modern imaging techniques and beyond (2017) (22)
- Preliminary results from KEYNOTE-055: Pembrolizumab after platinum and cetuximab failure in head and neck squamous cell carcinoma (HNSCC). (2016) (22)
- Gut Microbiome Associated with the Psychoneurological Symptom Cluster in Patients with Head and Neck Cancers (2020) (22)
- ACR Appropriateness Criteria® Aggressive Nonmelanomatous Skin Cancer of the Head and Neck (2016) (21)
- Concurrent chemoradiotherapy with weekly versus triweekly cisplatin in locally advanced squamous cell carcinoma of the head and neck: Comparative analysis (2019) (21)
- Head and neck PET/CT therapy response interpretation criteria (Hopkins criteria) - external validation study. (2017) (21)
- Prognosis of subglottic carcinoma: Is it really worse? (2018) (21)
- Metastatic signet-ring cell adenocarcinoma to the urinary bladder. (1997) (20)
- Nivolumab (Nivo) vs investigator’s choice (IC) for platinum-refractory (PR) recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN; Checkmate 141): Outcomes in first-line (1L) R/m patients and updated safety and efficacy. (2017) (20)
- Concurrent Cetuximab and Nivolumab as a Second-Line or beyond Treatment of Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results of Phase I/II Study (2021) (20)
- Current management of stage IV nasopharyngeal carcinoma without distant metastasis. (2020) (20)
- Inositol-triphosphate 3-kinase B confers cisplatin resistance by regulating NOX4-dependent redox balance. (2019) (20)
- Systemic therapy in non-conventional cancers of the larynx. (2018) (20)
- Combination of erlotinib and EGCG induces apoptosis of head and neck cancers through posttranscriptional regulation of Bim and Bcl-2 (2015) (19)
- ACR appropriateness criteria® nasal cavity and paranasal sinus cancers (2017) (19)
- Human papillomavirus oncoprotein E6 upregulates c-Met through p53 downregulation. (2016) (19)
- Bevacizumab in Combination with Taxane versus Non-Taxane Containing Regimens for Advanced/Metastatic Nonsquamous Non–Small-Cell Lung Cancer: A Systematic Review (2015) (18)
- Multicenter phase II trial of palbociclib, a selective cyclin dependent kinase (CDK) 4/6 inhibitor, and cetuximab in platinum-resistant HPV unrelated (-) recurrent/metastatic head and neck squamous cell carcinoma (RM HNSCC). (2018) (18)
- Clinical outcomes in elderly patients with human papillomavirus–positive squamous cell carcinoma of the oropharynx treated with definitive chemoradiation therapy (2016) (18)
- The role of the gut microbiome in cancer-related fatigue: pilot study on epigenetic mechanisms (2020) (18)
- Targeting the EGFR and Immune Pathways in Squamous Cell Carcinoma of the Head and Neck (SCCHN): Forging a New Alliance (2019) (17)
- Abstract CT021: Tumor-associated immune cell PD-L1 expression and peripheral immune profiling: Analyses from CheckMate 141 (2017) (17)
- Concurrent therapy with taxane versus non-taxane containing regimens in locally advanced squamous cell carcinomas of the head and neck (SCCHN): a systematic review. (2014) (17)
- Epigenetic age acceleration, fatigue, and inflammation in patients undergoing radiation therapy for head and neck cancer: A longitudinal study (2021) (17)
- Smoking, age, nodal disease, T stage, p16 status, and risk of distant metastases in patients with squamous cell cancer of the oropharynx (2018) (17)
- How phenotype guides management of non-conventional squamous cell carcinomas of the larynx? (2017) (17)
- Honokiol Radiosensitizes Squamous Cell Carcinoma of the Head and Neck by Downregulation of Survivin (2017) (17)
- LBA36 Nivolumab (N) + ipilimumab (I) vs EXTREME as first-line (1L) treatment (tx) for recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Final results of CheckMate 651 (2021) (17)
- Updated report of a phase II randomized trial of transoral surgical resection followed by low-dose or standard postoperative therapy in resectable p16+ locally advanced oropharynx cancer: A trial of the ECOG-ACRIN cancer research group (E3311). (2021) (16)
- Hsp90B enhances MAST1-mediated cisplatin resistance by protecting MAST1 from proteosomal degradation. (2019) (16)
- Differential regulation of NF-kB and IRF target genes as they relate to fatigue in patients with head and neck cancer (2018) (16)
- Multimodal Therapy for Sinonasal Malignancies: Updates and Review of Current Treatment (2020) (16)
- Concurrent chemotherapy with intensity‐modulated radiation therapy for locally advanced squamous cell carcinoma of the larynx and oropharynx: A retrospective single‐institution analysis (2009) (16)
- Association of Cytoplasmic CXCR4 With Loss of Epithelial Marker and Activation of ERK1/2 and AKT Signaling Pathways in Non–Small‐Cell Lung Cancer (2017) (15)
- The Role of Bisphosphonates in the Management of Advanced Cancer with a Focus on Non-Small-Cell Lung Cancer (2005) (15)
- 916MO Safety and efficacy of MEDI0457 plus durvalumab in patients (pts) with human papillomavirus-associated recurrent/metastatic head and neck squamous cell carcinoma (HPV+ R/M HNSCC) (2020) (15)
- RNA Based Approaches to Profile Oncogenic Pathways From Low Quantity Samples to Drive Precision Oncology Strategies (2021) (15)
- Adenosquamous Carcinoma of the Esophagus: An NCDB-Based Investigation on Comparative Features and Overall Survival in a Rare Tumor (2017) (15)
- Chemoprevention strategies for patients with lung cancer in the context of screening. (2005) (14)
- Is There a Role for PET/CT Parameters to Characterize Benign, Malignant, and Metastatic Parotid Tumors? (2016) (14)
- Nanotechnology and Drug Delivery: An Update in Oncology (2011) (14)
- Small Cell and Squamous Cell Carcinomas of the Head and Neck: Comparing Incidence and Survival Trends Based on Surveillance, Epidemiology, and End Results (SEER) Data. (2019) (14)
- ACR Appropriateness Criteria® Locoregional therapy for resectable oropharyngeal squamous cell carcinomas (2016) (14)
- The Role of Bisphosphonates in the Management of Advanced Cancer with a Focus on Non-Small-Cell Lung Cancer (2005) (14)
- Resilience and Biomarkers of Health Risk in Black Smokers and Nonsmokers (2017) (13)
- The Evolving and Future Role of Taxanes in Squamous Cell Carcinomas of the Head and Neck: A Review. (2016) (13)
- 18F-FDG-PET/CT parameters as imaging biomarkers in oral cavity squamous cell carcinoma, is visual analysis of PET and contrast enhanced CT better than the numbers? (2015) (13)
- Parenteral Bevacizumab for the Treatment of Severe Respiratory Papillomatosis in an Adult Population (2020) (13)
- Survival Outcomes With Thoracic Radiotherapy in Extensive-Stage Small-Cell Lung Cancer: A Propensity Score-Matched Analysis of the National Cancer Database. (2019) (13)
- Targeting epidermal growth factor receptor for head and neck squamous cell carcinoma: still lost in translation? (2016) (13)
- Tumor Membrane Vesicle Vaccine Augments the Efficacy of Anti-PD1 Antibody in Immune Checkpoint Inhibitor-Resistant Squamous Cell Carcinoma Models of Head and Neck Cancer (2020) (13)
- De-escalation studies in HPV-positive oropharyngeal cancer: How should we proceed? (2021) (13)
- Intra-Cranial Lesions in a Patient with Hodgkin Lymphoma (2004) (12)
- Targeted therapies in small-cell lung cancer (2007) (12)
- Prognostic value of radiographically defined extranodal extension in human papillomavirus‐associated locally advanced oropharyngeal carcinoma (2019) (12)
- Clinical efficacy of targeted biologic agents as second-line therapy of advanced thyroid cancer. (2013) (12)
- Cisplatin-mediated activation of glucocorticoid receptor induces platinum resistance via MAST1 (2021) (12)
- Prognostic implications of peritumoral vasculature in head and neck cancer (2018) (12)
- Exhaled breath analysis in the diagnosis of head and neck cancer (2019) (11)
- Commentary: Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study) (2017) (11)
- Biomarker quantification by multiplexed quantum dot technology for predicting lymph node metastasis and prognosis in head and neck cancer (2016) (11)
- ACR Appropriateness Criteria® thyroid carcinoma. (2014) (11)
- Racial Disparities, Outcomes, and Surgical Utilization among Hispanics with Esophageal Cancer: A Surveillance, Epidemiology, and End Results Program Database Analysis (2019) (11)
- ACR Appropriateness criteria® for nasopharyngeal carcinoma (2016) (11)
- Optimizing systemic therapy in squamous cell carcinoma of the head and neck with a focus on targeted agents (2009) (11)
- Small cell and large cell neuroendocrine carcinoma of the larynx: A comparative analysis. (2019) (10)
- Technology evaluation: mapatumumab, Human Genome Sciences/GlaxoSmithKline/Takeda. (2005) (10)
- Phase III randomized trial of chemotherapy with or without bevacizumab (B) in patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Survival analysis of E1305, an ECOG-ACRIN Cancer Research Group trial. (2017) (10)
- Concurrent cetuximab (CTX) and nivolumab (NIVO) in patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Results of phase II study. (2020) (10)
- Electronic Cigarettes and Head and Neck Cancer Risk—Current State of Art (2020) (10)
- Characterization of potential predictive biomarkers of response to nivolumab in CheckMate 141 in patients with squamous cell carcinoma of the head and neck (SCCHN). (2017) (9)
- The Future Prospects of Immune Therapy in Gastric and Esophageal Adenocarcinoma (2016) (9)
- Disparities in Postoperative Therapy for Salivary Gland Adenoid Cystic Carcinomas (2018) (9)
- Pembrolizumab after progression on platinum and cetuximab in head and neck squamous cell carcinoma (HNSCC): results from KEYNOTE-055 (2016) (9)
- 71P A phase II study of ADU-S100 in combination with pembrolizumab in adult patients with PD-L1+ recurrent or metastatic HNSCC: Preliminary safety, efficacy and PK/PD results (2020) (9)
- Two-year Update From CheckMate 141: Outcomes With Nivolumab (Nivo) vs Investigator's Choice (IC) in Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN) in the Overall Population and PD-L1 Subgroups (2018) (9)
- A Historic Perspective and Overview of H-Ras Structure, Oncogenicity, and Targeting (2020) (9)
- Association of epigenetic age acceleration with risk factors, survival, and quality of life in patients with head and neck cancer. (2021) (9)
- EGFR Monoclonal Antibodies in the Treatment of Squamous Cell Carcinoma of the Head and Neck: A View beyond Cetuximab (2012) (9)
- Combinatorial approaches targeting the EGFR family and c-Met in SCCHN. (2020) (9)
- A Randomized, Open-Label, Multicenter, Global Phase 2 Study of Durvalumab (D), Tremelimumab (T), or D Plus T in Patients With PD-L1 Low/Negative Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC): CONDOR (2018) (9)
- American college of radiology appropriateness criteria® treatment of stage I T1 glottic cancer (2014) (8)
- ATAD3A mediates activation of RAS-independent mitochondrial ERK1/2 signaling, favoring head and neck cancer development (2022) (8)
- Nivolumab (nivo) vs investigator’s choice (IC) in patients (pts) with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Analysis of CheckMate 141 by age. (2018) (8)
- Phase II multi-institutional clinical trial result of concurrent cetuximab and nivolumab in recurrent and/or metastatic head and neck squamous cell carcinoma. (2022) (8)
- Novel targeted agents in the treatment of lung cancer (2004) (8)
- The Proteomic Landscape of Growth Factor Signaling Networks Associated with FAT1 Mutations in Head and Neck Cancers (2021) (8)
- Refractory acquired von Willebrand disease despite successful treatment of the associated lymphoma. (2002) (7)
- ACR Appropriateness Criteria: local-regional therapy for resectable oropharyngeal squamous cell carcinomas. (2010) (7)
- Phase Ib Study of Chemoprevention with Green Tea Polyphenon E and Erlotinib in Patients with Advanced Premalignant Lesions (APL) of the Head and Neck (2020) (7)
- Chemoprevention in lung cancer. (2002) (7)
- Current treatment of T1N0 squamous cell carcinoma of the glottic larynx (2015) (7)
- Deformable registration of histological cancer margins to gross hyperspectral images using demons (2018) (7)
- TP53 mutations in head and neck cancer (2022) (7)
- Everolimus, an mTOR inhibitor, in combination with docetaxel for second- or third-line therapy of advanced-stage non-small cell lung cancer: A phase II study. (2011) (7)
- Application of Artificial Intelligence for Nasopharyngeal Carcinoma Management – A Systematic Review (2022) (7)
- The Hidden Link of Exosomes to Head and Neck Cancer (2021) (7)
- Molecular biological design of novel antineoplastic therapies (2004) (7)
- Abstract PR08: Preliminary results from a phase 2 trial of tipifarnib in squamous cell carcinomas (SCCs) with HRAS mutations (2019) (7)
- Tumor infiltrating lymphocytes after neoadjuvant IRX-2 immunotherapy in oral squamous cell carcinoma: Interim findings from the INSPIRE trial. (2020) (7)
- Early response dynamics predict treatment failure in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with cetuximab and nivolumab. (2022) (6)
- Mo1135 Trends in the Incidence of Esophageal Adenocarcinoma and Early Stage Esophageal Adenocarcinoma in the United States (2014) (6)
- Salvage surgery for squamous cell carcinoma of the head and neck in the era of immunotherapy: Is it time to clarify our guidelines? (2018) (6)
- HIV-Associated Lung Cancer in the Era of Highly Active Antiretroviral Therapy (HAART) (2012) (6)
- A 39-bp deletion polymorphism in PTEN in African American individuals: implications for molecular diagnostic testing. (2002) (6)
- Complete Remission of Acute Myeloid Leukemia following Cisplatin Based Concurrent Therapy with Radiation for Squamous Cell Laryngeal Cancer (2016) (6)
- Posttreatment Imaging in Patients with Head and Neck Cancer without Clinical Evidence of Recurrence: Should Surveillance Imaging Extend Beyond 6 Months? (2020) (6)
- Survival advantage of chemoradiotherapy in anaplastic thyroid carcinoma: Propensity score matched analysis with multiple subgroups (2019) (6)
- Current Aspects and Future Considerations of EGFR Inhibition in Locally Advanced and Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck (2021) (6)
- A randomized phase II study of tremelimumab and durvalumab with or without radiation for patients with relapsed small cell lung cancer (SCLC). (2019) (6)
- Blockade of glutamine-dependent cell survival augments antitumor efficacy of CPI-613 in head and neck cancer (2021) (6)
- CT Accuracy of Extrinsic Tongue Muscle Invasion in Oral Cavity Cancer (2017) (5)
- Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651 (2022) (5)
- Comparison of concurrent use of carboplatin-Paclitaxel versus cisplatin-etoposide with thoracic radiation for stage III NSCLC patients: A systematic review. (2015) (5)
- The omission of intentional primary site radiation following transoral robotic surgery in 59 patients: No local‐regional failures (2021) (5)
- Simultaneous occurrence of polycythemia vera and Waldenstrom macroglobulinemia: a case report and review of the literature. (2002) (5)
- Cetuximab with or without sorafenib in recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). (2013) (5)
- Association Among Glucocorticoid Receptor Sensitivity, Fatigue, and Inflammation in Patients With Head and Neck Cancer (2020) (5)
- Interleukin-6/STAT3 Signaling is Prominent and Associated with Reduced Overall Survival in p16 Negative Oropharyngeal Squamous Cell Carcinoma (2018) (5)
- Soy Isoflavone Supplementation Increases Long Interspersed Nucleotide Element-1 (LINE-1) Methylation in Head and Neck Squamous Cell Carcinoma (2019) (5)
- Socioeconomic Factors Influence the Impact of Tumor HPV Status on Outcome of Patients With Oropharyngeal Squamous Cell Carcinoma. (2021) (5)
- T4 Laryngeal Cancer With Good Function: Should We Be Reluctant to Treat Without Surgery? (2018) (5)
- Advances in Targeting HER 3 as an Anticancer Therapy (5)
- Chemoprevention with erlotinib and celecoxib in advanced premalignant lesions of the head and neck: Results of a phase I study. (2010) (5)
- Development of Late Toxicities in Patients with Oral Tongue Cancer Treated with Surgical Resection and Adjuvant Radiation Therapy (2017) (5)
- A novel prediction model for human papillomavirus-associated oropharyngeal squamous cell carcinoma using p16 and subcellular β-catenin expression. (2016) (5)
- Phase 2 study of dalantercept in recurrent or metastatic squamous cell carcinoma of the head and neck. (2014) (5)
- Incidence of Cancer Treatment–Induced Arrhythmia Associated With Novel Targeted Chemotherapeutic Agents (2018) (5)
- Abstract CT157: Treatment beyond progression with nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck in the phase 3 Checkmate 141 study (2017) (5)
- Nasal Cavity and Paranasal Sinus Cancers (2016) (5)
- Demographic and Socioeconomic Factors Associated With Metastases at Presentation in HPV-Related Squamous Cell Carcinoma of the Head and Neck: An NCDB Analysis. (2020) (5)
- Targeting angiogenesis in head and neck cancer. (2007) (5)
- Co-expression of fibroblast growth factor receptor 3 with mutant p53, and its association with worse outcome in oropharyngeal squamous cell carcinoma (2021) (5)
- Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141 (2022) (4)
- Pembrolizumab in previously treated metastatic esophageal cancer: Longer term follow-up from the phase 2 KEYNOTE-180 Study. (2019) (4)
- Pulmonary sarcomatoid carcinoma: An analysis of the National Cancer Database. (2015) (4)
- Role of COX-2 in tumor progression and survival of head and neck squamous cell carcinoma (4)
- Prognostic biomarkers in patients with human immunodeficiency virus‐positive disease with head and neck squamous cell carcinoma (2017) (4)
- Moving toward bioadjuvant approaches to head and neck cancer prevention. (2007) (4)
- Esophageal Cancer: Prevention, Diagnosis and Therapy (2016) (4)
- immunotherapy of cancerActive8: A randomized, double-blind, placebo-controlled study of chemotherapy plus cetuximab in combination with motolimod immunotherapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (2016) (4)
- A phase 1b/2a, multi-center, open-label study to evaluate the safety and efficacy of combination treatment with MEDI0457 (INO-3112) and durvalumab (MEDI4736) in patients with recurrent/metastatic human papilloma virus–associated head and neck squamous cell cancer. (2018) (4)
- Is there a role for PET/CT parameters to differentiate thyroid cartilage invasion from penetration? (2016) (4)
- FOR SQUAMOUS CELL CARCINOMA OF THE TONSIL (2012) (4)
- Phase IB Study of Induction Chemotherapy With XELOX, Followed by Radiation Therapy, Carboplatin, and Everolimus in Patients With Locally Advanced Esophageal Cancer (2019) (4)
- Concurrent chemoradiation using weekly versus tri-weekly cisplatin in locally advanced squamous cell carcinoma of the head and neck (SCCHN): A comparative analysis. (2015) (4)
- A phase 3 randomized, double-blind, placebo-controlled, multicenter, global study of durvalumab with and after chemoradiotherapy in patients with locally advanced, unresectable esophageal squamous cell carcinoma: KUNLUN. (2022) (4)
- A phase I study of the safety and pharmacodynamic effects of everolimus in combination with lenalidomide in patients with advanced solid malignancies. (2012) (4)
- Everolimus, an mTOR inhibitor, in combination with docetaxel for recurrent/refractory NSCLC: A phase I study. (2009) (4)
- Narrowband Imaging for p16+ Unknown Primary Squamous Cell Carcinoma Prior to Transoral Robotic Surgery (2020) (4)
- Human papillomavirus (HPV)-associated early stage non-small cell lung cancer (NSCLC). (2013) (4)
- T cell repertoire in peripheral blood as a potential biomarker for predicting response to concurrent cetuximab and nivolumab in head and neck squamous cell carcinoma (2022) (4)
- A phase II study of dasatanib (BMS 354825) in recurrent or metastatic ckit-expressing adenoid cystic (ACC) and non-ACC malignant salivary glands tumors (MSGT). (2013) (4)
- Poster ViewingCirculating Pre-treatment miRNAs as Potential Biomarkers to Predict Radiation Toxicity (2017) (4)
- A phase II/III study of perioperative nivolumab and ipilimumab in patients (pts) with locoregional esophageal (E) and gastroesophageal junction (GEJ) adenocarcinoma: Results of a safety run-in—A trial of the ECOG-ACRIN Cancer Research Group (EA2174). (2021) (4)
- Randomized phase II trial of ficlatuzumab with or without cetuximab in pan-refractory, advanced head and neck squamous cell carcinoma (HNSCC). (2021) (3)
- Antitumor Activity of 2,9-Di-Sec-Butyl-1,10-Phenanthroline (2016) (3)
- Trimodality therapy in the treatment of stage IIIA non-small cell lung cancer (NSCLC): Analysis of the National Cancer Database. (2015) (3)
- Signatures of somatic mutations and gene expression from p16INK4A positive head and neck squamous cell carcinomas (HNSCC) (2020) (3)
- Heregulin and HER 3 Are Prognostic Biomarkers in Oropharyngeal Squamous Cell Carcinoma (3)
- A network analysis of self‐reported psychoneurological symptoms in patients with head and neck cancer undergoing intensity‐modulated radiotherapy (2022) (3)
- A phase II trial of pembrolizumab and cabozantinib in patients (pts) with recurrent metastatic head and neck squamous cell carcinoma (RMHNSCC). (2022) (3)
- A randomized, double-blind phase II study of pembrolizumab versus placebo in patients with head and neck cancers at high risk for recurrence or low-volume residual disease: The PATHWay Study. (2017) (3)
- Targeting Angiogenesis in Squamous Cell Carcinoma of the Head and Neck: Opportunities in the Immunotherapy Era (2022) (3)
- Esophagogastric junction and gastric adenocarcinoma: current challenges and future directions. (2014) (3)
- Abstract CT116: Nivolumab (Nivo) vs investigator's choice (IC) in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): 2-yr outcomes in the overall population and PD-L1 subgroups of CheckMate 141 (2018) (3)
- A phase II/III study of perioperative nivolumab and ipilimumab in patients (pts) with locoregional esophageal (E) and gastroesophageal junction (GEJ) adenocarcinoma: A trial of the ECOG-ACRIN Cancer Research Group (EA2174). (2020) (3)
- CDX3379-04: Phase II evaluation of CDX-3379 in combination with cetuximab in patients with advanced head and neck squamous cell carcinoma (HNSCC). (2019) (3)
- 1055PNivolumab vs investigator’s choice (IC) in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): treatment effect on clinical outcomes by best overall response in checkmate 141 (2017) (3)
- 352 Treatment Allocation in Early Stage Esophageal Adenocarcinoma: the National Incidence Rates and Predictors of Lymph Node Involvement (2014) (3)
- Survival impact of newly approved therapeutic agents in patients with advanced non-small cell lung cancer (NSCLC): A SEER-Medicare database analysis. (2010) (3)
- Incidence trends of squamous cell carcinoma of the head and neck (SCCHN) in the aging population––A SEER‐based analysis from 2000 to 2016 (2021) (3)
- Biomarkers predictive of response to pembrolizumab in head and neck cancer (2022) (3)
- Preoperative chemotherapy for sinonasal squamous cell carcinoma (SNSCC): Time to move closer to a definitive answer (2021) (2)
- Racial disparities in the incidence and survival trends in women with squamous cell carcinoma of the oral tongue based on the Surveillance, Epidemiology, and End Results (SEER) analysis. (2014) (2)
- Survival outcomes by HPV status in non-oropharyngeal head and neck cancers: A propensity score matched analysis of population level data. (2018) (2)
- Efficacy of concurrent cetuximab (CTX) and nivolumab (NIVO) in previously untreated recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). (2021) (2)
- The diverse functions of FAT1 in cancer progression: good, bad, or ugly? (2022) (2)
- The AIM-HN Study: A pivotal study evaluating the efficacy of tipifarnib in patients with recurrent or metastatic head and neck squamous cell carcinoma with HRAS mutations. (2021) (2)
- Abstract CT016: Integrated biomarker trials of VX15/2503 (pepinemab) in combination with checkpoint inhibitors in window of opportunity studies in solid tumors (2019) (2)
- Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers: ASCO Guideline (2022) (2)
- Outcomes and Predictive Value of Post‐adjuvant Therapy PET/CT for Locally Advanced Oral Squamous Cell Carcinoma (2020) (2)
- Cancer of the Paranasal Sinuses. (2021) (2)
- Evaluating new treatments for anaplastic thyroid cancer (2022) (2)
- Carboplatin (C), cetuximab (Cet), and everolimus (E) in recurrent or metastatic squamous cell carcinoma of the head and neck (RMSCCHN). Results of a phase Ib study. (2013) (2)
- Locally advanced high-risk HPV related oropharyngeal squamous cell carcinoma (OPSCC); have we forgotten it is a different disease? (2018) (2)
- Incidence trends of squamous cell carcinoma of the head and neck (SCCHN) in the aging population: A SEER based analysis from 2000-2016. (2020) (2)
- Phase II Trial of CDX-3379 and Cetuximab in Recurrent/Metastatic, HPV-Negative, Cetuximab-Resistant Head and Neck Cancer (2022) (2)
- A phase 2, multicenter, open-label study to evaluate the efficacy and safety of CDX-3379 in combination with cetuximab in patients with advanced head and neck squamous cell carcinoma (HNSCC). (2018) (2)
- Diagnosis and Multidisciplinary Treatment of Laryngeal Cancers (2011) (2)
- ADJUVANT THERAPY FOR RESECTED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (2011) (2)
- Dual Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor 2 Inhibition in Squamous Cell Carcinoma of the Head and Neck; Is the Jury Still Out? (2016) (2)
- TRYHARD, a randomized phase II trial (RTOG Foundation 3501) of concurrent accelerated radiation plus cisplatin (cis) with or without lapatinib (Lap) for stage III- IV Non-HPV head and neck carcinoma (HNC). (2021) (1)
- Abstract 515: Survivin contributes to radiation resistance in head and neck cancer through regulation of DNA damage repair (2016) (1)
- HIV-associated lung cancer in the era of highly active antiretroviral therapy (HAART): Correlation between CD4 count and outcome. (2010) (1)
- Epigenetic Mechanisms of Inflammation and Fatigue in Patients With Cancer (2018) (1)
- Malignancies of the Paranasal Sinuses and Skull Base (2018) (1)
- Comparison of the seventh and eighth editions of the American Joint Committee on Cancer (AJCC) staging for oropharyngeal squamous cell carcinomas (OPSCC): A Surveillance, Epidemiology and End Results Program (SEER) database analysis. (2019) (1)
- Epstein-Barr virus directed screening for nasopharyngeal carcinoma in individuals with positive family history: A systematic review. (2022) (1)
- Phase II study of dalantercept, a novel inhibitor of ALK1-mediated angiogenesis, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. (2013) (1)
- FGFR3 correlation with mutant p53 and its prognostic value in oropharyngeal squamous cell carcinoma (OPSCC). (2017) (1)
- Breath analysis for early detection of lung cancer. (2012) (1)
- ICR gene signature to identify differential immune landscapes in anatomic subsites of head and neck squamous cell carcinomas and implications in personalized medicine. (2018) (1)
- Trends in small cell lung cancer (SCLC) survival: Predictors and impact of systemic therapy. (2014) (1)
- The Challenges of Laryngeal Preservation-Is It the Systemic Agent or the Proper Sequence of Therapy? (2016) (1)
- Large Molecule Therapeutics Combination of Anti-HER 3 Antibody MM-121 / SAR 256212 and Cetuximab Inhibits Tumor Growth in Preclinical Models of Head and Neck Squamous Cell Carcinoma (2014) (1)
- Predictive value of gene expression signatures in premalignant lesions of the head and neck for response to chemoprevention with EGFR and COX-2 inhibitors. (2014) (1)
- Oncologic Outcomes After Clinically Node-Negative Salvage Laryngectomy. (2022) (1)
- Tipifarnib enhances anti-EGFR activity of cetuximab in non-HRas mutated head and neck squamous cell carcinoma cancer (HNSCC). (2021) (1)
- Otorhinolaryngological Toxicities of New Drugs in Oncology (2017) (1)
- Racial disparities in surgical management and survival in hispanic patients with potentially resectable esophageal cancer. (2018) (1)
- Pre-medications for cetuximab induced infusion reactions - commentary. (2014) (1)
- Characterization of a Novel Mouse Model of Spontaneous Human Lung Cancer Metastasis (2019) (1)
- Comparison of the Seventh and Eighth Edition of American Joint Committee on Cancer (AJCC) Staging for Selected and Nonselected Oropharyngeal Squamous Cell Carcinomas (2022) (1)
- Expressions of EGFR, HER2, and HER3 and their correlations with clinical characteristics in oropharyngeal squamous cell carcinoma (OPSCC). (2014) (1)
- Combination of erlotinib and EGCG induces apoptosis of head and neck cancers through posttranscriptional regulation of Bim and Bcl-2 (2015) (1)
- Neighborhood socioeconomic disadvantage, tobacco use, and cessation indicators among adults with cancer in the United States: Results from 10 ECOG-ACRIN trials. (2022) (1)
- Safety of nivolumab added to chemoradiotherapy platforms for intermediate and high-risk local-regionally advanced head and neck squamous cell carcinoma: RTOG Foundation 3504. (2022) (1)
- Hsp 90 B enhances MAST 1-mediated cisplatin resistance by protecting MAST 1 from proteosomal degradation (2019) (1)
- Dual targeting of EGFR and HER3 with cetuximab and MM-121/SAR256212 in HNSCC patient derived xenograft (PDX) models. (2015) (1)
- Refining the predictors of outcome in patients with resectable esophageal cancer (2017) (1)
- 354 A phase 1 trial of CUE-101 a novel HPV16 E7-pHLA-IL2-Fc fusion protein in patients with recurrent/metastatic HPV16+ head and neck cancer (2020) (1)
- Systemic bevacizumab for the treatment of recurrent respiratory papillomatosis: A retrospective analysis from an academic tertiary care center (2019) (1)
- Patterns of head and neck cancer incidence, mortality, and survival in the U.S. Hispanic population. (2017) (1)
- Abstract B268: A Phase I Study of CUDC-101, a multitarget inhibitor of HDACs, EGFR, and HER2, in combination with chemoradiation in patients with intermediate/high risk locally advanced squamous cell carcinoma of the head and neck. (2013) (1)
- Epidemiology of early esophageal adenocarcinoma (2022) (1)
- Patient-derived xenografts faithfully replicated clinical outcome in a phase II co-clinical trial of arsenic trioxide in relapsed small cell lung cancer (2016) (1)
- Designing and Conducting Phase III Studies (2010) (1)
- Landscape of genetic alterations in oropharyngeal squamous cell carcinoma (OPSCC) based on RNA-seq and WES analysis of FFPE samples and correlation with data from TCGA. (2017) (1)
- Abstract 1545: Altered myeloid and lymphoid composition of tumor microenvironment following anti-SEMA4D and immune checkpoint combination therapies (2019) (1)
- The Quest to Eradicate HPV-Related Oropharyngeal Carcinoma: An Opportunity Not to Miss. (2022) (1)
- Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States (2023) (1)
- Prognostic Value of Radiographically-Defined Extranodal Extension is Modulated by Human Papillomavirus Status in Locally Advanced Oropharyngeal Carcinoma (2017) (1)
- Abstract 4834: Effective treatment of squamous cell carcinoma of the head and neck (HNSCC) using a combined regimen of tipifarnib and cetuximab (2019) (1)
- A Multicenter Randomized Phase II Study of Single Agent Efficacy and Optimal Combination Sequence of Everolimus and Pasireotide LAR in Advanced Thyroid Cancer (2022) (1)
- Systematic comparative analysis of efficacy of EGFR tyrosine kinase inhibitors (TKIs) in the frontline versus salvage therapy of NSCLC. (2011) (1)
- Association of Preoperative Radiographic Nodal Status in Addition to Traditional Pathologic Factors With Outcomes in Patients With Laryngeal or Oral Cavity Cancer Managed With Initial Surgery (2013) (1)
- Incidence of Cancer Treatment Induced Arrhythmia Associated with Immune Checkpoint Inhibitors. (2021) (1)
- Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trial (2023) (1)
- Phase 1/2 study of pepinemab, an inhibitor of semaphorin 4D, in combination with pembrolizumab as first-line treatment of recurrent or metastatic head and neck cancer (KEYNOTE-B84). (2022) (0)
- Research Report Bone Marrow Transplantation for Nonmalignant Diseases (2002) (0)
- Outcomes stratification of head and neck cancer using pre- and post-treatment DNA methylation from peripheral blood. (2022) (0)
- Abstract 2980: Effects of cetuximab and CD-3379 on cytokine/chemokine balance in the tumor micro-environment (TME) of squamous cell carcinoma of the head and neck (SCCHN) (2020) (0)
- Proton Beam Radiation Therapy for Oropharyngeal Squamous Cell Carcinoma (2023) (0)
- To scan or not to scan: the dilemma of post-treatment imaging surveillance of head and neck cancer. (2022) (0)
- The impact of operability status on outcomes in patients with T4 larynx cancer undergoing larynx preservation (2022) (0)
- Does Operability Status Influence Outcomes in Patients With T4 Larynx Cancer Undergoing Larynx Preservation? (2021) (0)
- Landscape of genetic alterations in non-smoking patients with oral tongue carcinoma: An analysis of The Cancer Genome Atlas (TCGA) head and neck squamous cell carcinoma data. (2015) (0)
- Evaluation of ALDH1-A1 as a biomarker for metastasis of head and neck cancer. (2010) (0)
- Abstract A15: Integrated biomarker trials to evaluate myeloid and lymphoid composition of HNSCC and solid tumors treated with pepinemab and combinations with checkpoint inhibitors (2020) (0)
- Phase IB study of induction chemotherapy with XELOX, followed by radiation therapy, carboplatin, and everolimus in patients with locally advanced esophageal cancer (EC). (2017) (0)
- The Epidemiology of Esophageal Adenocarcinoma in the United States: Presidential Poster Award (2018) (0)
- Abstract 876: Effective reduction of PD-L1 expression by simultaneous blockade of EGFR and HER3 (ErbB3) in head and neck cancer (2018) (0)
- INCIDENCE OF CANCER TREATMENT-INDUCED ARRHYTHMIA ASSOCIATED WITH NOVEL TARGETED CHEMOTHERAPEUTIC AGENTS (2018) (0)
- Acetylated tubulin and risk of nodal metastases in squamous cell carcinoma of the head and neck (SCCHN). (2012) (0)
- Small cell carcinoma of the head and neck: Incidence and survival trends based on the Surveillance and Epidemiologic and End Results (SEER) analysis. (2017) (0)
- Plasma Metabolic Phenotypes of HPV-Associated versus Smoking-Associated Head and Neck Cancer and Patient Survival (2021) (0)
- Survival Advantage to Combined Modality Therapy Seen in Multiple Subgroups Within Anaplastic Thyroid Carcinoma: A Propensity-Score Matched Analysis of the National Cancer Data Base (2018) (0)
- The diverse functions of FAT1 in cancer progression: good, bad, or ugly? (2022) (0)
- Phase 1b study of chemoprevention with green tea polyphenon E (PPE) and epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (Erlotinib) in patients (pts) with advanced premalignant (AP) lesions of the head and neck. (2019) (0)
- Lymphovascular Space Invasion Is Independently Predictive of Local and Regional Failure and Reduced Survival in Node-Negative Oral Tongue Cancers (2016) (0)
- Effect of definitive concurrent therapy with or without surgery on resectable esophageal cancer survival: An analysis of the National Cancer Data Base. (2016) (0)
- Abstract 1852: Enhancing specificity in predication of human papillomavirus associated oropharyngeal squamous cell carcinoma by combining biomarkers p16 and β-catenin (2014) (0)
- Molecular signatures of class II HLA and p-16 status as an immune-based classification of OPSCC relying on known predictors of sensitivity to PD-1 blockade. (2017) (0)
- Abstract 500: Neuropsychological symptoms in patients with head and neck cancer undergoing radiation therapy: A network analysis (2022) (0)
- Immune check point inhibitors in advanced cutaneous squamous cell carcinomas: “Repeat and replicate” (2022) (0)
- Abstract 321: Identification of proteins associated withFAT1mutations which potentially contribute to oncogenesis and progression of head and neck cancers (2021) (0)
- Outcomes and Predictive Value of Post-Adjuvant Therapy Surveillance PET/CECT for Locally Advanced Oral Squamous Cell Carcinoma (2020) (0)
- Defining HPV-specific B cell responses in head and neck cancer patients (2020) (0)
- Radiation Dose Escalation Is Associated With Improved Survival in Cervical Esophageal Cancer (2016) (0)
- Factors associated with metastatic presentation in HPV-related squamous cell carcinoma of the head and neck (SCCHN): A National Cancer Database (NCDB) analysis. (2019) (0)
- Chemoprevention in Head and Neck Cancer (2005) (0)
- Abstract 813: Human papillomavirus 16 oncoprotein E6 upregulates c-Met partially through p53 in squamous cell carcinoma of the head and neck (2015) (0)
- Predictors and outcomes of venous thromboembolism (VTE) in hospitalized lung cancer patients: A nationwide inpatient sample (NIS) database analysis. (2014) (0)
- Comparison of the 7th and 8th editions of the American Joint Committee on Cancer (AJCC) staging for oropharyngeal squamous cell carcinomas (OPSCC): A Surveillance, Epidemiology and End Results Program (SEER) database analysis (2020) (0)
- Chemotherapy and molecularly targeted therapies for previously untreated SCCHN (2013) (0)
- With amino functional silane modified epoxy resin and coatings produced therefrom for sealing strips. (1992) (0)
- Management of Older Patients with Head and Neck Cancer: A Comprehensive Review. (2023) (0)
- Survival outcomes of nonoperative therapy (NOT) alone versus NOT followed by surgery (NOTS) in patients with esophageal cancer (EC): SEER analysis 2000-2007. (2011) (0)
- Clinical Trial Development in TP53-Mutated Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. (2022) (0)
- P1.01-035 Trends, Patterns of Treatment and Outcomes in Non-Small Cell Lung Cancer (NSCLC) as a Second Primary: A National Cancer Data Base (NCDB) Analysis: Topic: Prognostic Factors, Treatment (2017) (0)
- AGGRESSIVE NONMELANOMATOUS SKIN CANCER OF THE HEAD AND NECK Panel on Radiation Oncology–Head (2015) (0)
- Evolution of standard of care therapies used for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): A real-world analysis of patient health records from 2016 to 2019. (2021) (0)
- Abstract 3026: Inhibition of glutaminolysis overcomes metabolic adaptation to devimistat treatment (2022) (0)
- Insurance authorization and access to proton therapy for patients with head and neck cancers. (2023) (0)
- Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers: ASCO Guideline Q and A. (2023) (0)
- Characterisation of Potential Predictive Biomarkers of Response to Nivolumab in Checkmate 141 in Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN) (2017) (0)
- RETREATMENT OF RECURRENT HEAD AND NECK CANCER AFTER PRIOR DEFINITIVE RADIATION (2012) (0)
- Abstract 3223: EGFR targeted iron-oxide nanoparticles for photodynamic therapy in head and neck cancer (2014) (0)
- Abstract 4110: Combinatory approaches targeting EGFR, HER2 and c-MET in recurrent SCCHN (2017) (0)
- The Relationship Between Radiation Dose And Overall Survival In Cervical Esophageal Cancer: An NCDB Analysis (2017) (0)
- Abstract LB-79: Combined treatment with HER3 antibody MM-121/SAR 256212 and EGFR antibody cetuximab in pre-clinical models of head and neck cancer. (2013) (0)
- Impact of neck failure on survival in older patients with differentiated thyroid cancer (2016) (0)
- Randomized, phase II study of ficlatuzumab with or without cetuximab in patients with pan-refractory, recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). (2020) (0)
- Abstract PO-033: Metabolic differences between human papillomavirus-related and smoking-related squamous cell carcinoma of the head and neck independently predict overall patient survival (2020) (0)
- Role of Nutrition in Squamous Cell Carcinoma of the Head and Neck (2017) (0)
- Increased Fatigue Is Associated With TNF and NFκB-Regulated Inflammatory Signaling in Patients With Head and Neck Cancer Receiving IMRT (2014) (0)
- Current Radiotherapy Considerations for Nasopharyngeal Carcinoma (2022) (0)
- Abstract 699: PIK3CA/BRAF mutations negatively affect outcome of patients with KRAS wild-type metastatic colorectal cancer treated with front line anti-EGFR monoclonal antibodies: Meta-analysis results (2015) (0)
- Abstract 3744: Acetylated tubulin (AT) levels predicts response to TPF chemotherapy in locally advanced head and neck squamous cell carcinoma (HNSCC) (2010) (0)
- ATAD3A mediates activation of RAS-independent mitochondrial ERK1/2 signaling, favoring head and neck cancer development (2022) (0)
- Abstract B038: Blockade of c-met signaling to circumvent radioresistance-associated metastasis in head and neck cancer (2022) (0)
- Vascular Targeting and Therapeutics for Squamous Cell Carcinoma of the Head and Neck (2006) (0)
- endothelial cells and monocytes positive microparticles derived from - Sickle blood contains tissue factor (2013) (0)
- The Effect of Hospital Volume and Insurance Status on Overall Survival in Sinonasal Carcinoma: A National Cancer Database (NCDB) Analysis (2018) (0)
- Chromosome Translocations, Gene Fusions, and Their Molecular Consequences in Pleomorphic Salivary Gland Adenomas (2022) (0)
- Designing and Building a Colocated Multidisciplinary Head and Neck Cancer Clinic (2022) (0)
- Abstract 4097: TMV vaccine inhibits growth of squamous cell carcinoma of head and neck in mice (2019) (0)
- Phase I and pharmacokinetic study of everolimus, an mTOR inhibitor, in combination with docetaxel for recurrent/refractory non-small cell lung cancer (0)
- Neutrophil to Lymphocyte Ratio in Oropharyngeal Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis (2023) (0)
- Blockade of glutamine-dependent cell survival augments antitumor efficacy of CPI-613 in head and neck cancer (2021) (0)
- Abstract 1428: Targeting RRM2 by siRNA inhibits cellular invasion and represents a rational approach for inhibition of metastasis of head and neck and lung cancers (2015) (0)
- Issue Information (2022) (0)
- A correlative analysis of PDL-1, PD-1, and EGFR, HER2, HER3 expression in oropharyngeal squamous cell carcinoma (OPSCC). (2016) (0)
- Concurrent platinum-based chemotherapy with intensity modulated radiation therapy (IMRT) for locally advanced squamous cell carcinoma of the head and neck (SCCHN): A retrospective single institution analysis (2007) (0)
- Transcriptional profiling of Tu212 cell line treated with EGCG and resveratrol to identify actionable targets for adjuvant therapy. (2014) (0)
- Abstract 5595: Statin drugs have anti-tumor activity and enhance responses to anti-PD-1 therapy in preclinical models of head and neck cancer (2022) (0)
- Pemetrexed versus taxane-containing platinum doublet therapy for advanced non-squamous non-small cell lung cancer (NSCLC): A systematic analysis. (2015) (0)
- Bevacizumab in combination with taxane versus non-taxane-containing regimens for advanced/metastatic nonsquamous non-small-cell lung cancer (NSCLC): A systematic review. (2013) (0)
- 0577 Sleep Quality and Its Association with Inflammation Over Time in Patients Undergoing Radiation Therapy for Head and Neck Cancer (2022) (0)
- Optimal thoracic radiation dose in limited stage small cell lung cancer. (2017) (0)
- Abstract 2326: Antiangiogenic effects associated with the inhibition of HSP90 in colorectal cancer (2012) (0)
- Monoclonal Antibodies against Epidermal Growth Factor Receptor in Solid Tumors (2012) (0)
- Enrollment into molecular selection trials and impact on patient disposition. (2017) (0)
- Ninety‐day mortality following transoral robotic surgery or radiation at Commission on Cancer‐accredited facilities (2022) (0)
- Persistent Fatigue Is Associated With Persistent Peripheral Inflammation in Patients With Squamous Cell Carcinoma of the Head and Neck Cancer up to 3 Months Post-Intensity Modulated Radiation Therapy (2016) (0)
- Abstract 4798: Subcellular translocation of β-catenin and its relationship with EGFR activation in HPV16 positive OPSCC. (2013) (0)
- Integrated Biomarker Study of Pepinemab in Combination with Nivolumab or Ipilimumab to Evaluate Immune Cell Composition of TME in Patients with Head and Neck Squamous Cell Carcinoma and Other Solid Tumors (2020) (0)
- TREATMENT OF STAGE I T1 GLOTTIC CANCER (2013) (0)
- A retrospective cohort study of inpatient chemotherapy utilization in hospitalized advanced lung cancer patients in the United States. (2013) (0)
- Heat shock protein 90 (HSP90) inhibition in squamous cell carcinoma of the head and neck (SCCHN): An in vitro analysis with a focus on p16 status. (2013) (0)
- Non-small cell lung cancer (NSCLC) as a second primary: Analysis of the National Cancer Data Base (NCDB). (2016) (0)
- Abstract 4498: Prognostic significance of nuclear factor kappa B expression in human papillomavirus-associated oropharyngeal cancer (2012) (0)
- Acknowledgement to the Reviewers (2011) (0)
- Multimodality Management of Esophageal Malignancies beyond Endoscopy (2015) (0)
- Institutional treatment volume and outcomes in salivary gland cancer. (2017) (0)
- HPV status is associated with fatigue and inflammation in patients with squamous cell carcinoma of the Head and Neck from pre to up to 3 Months Post IMRT (2017) (0)
- Adenoid cystic carcinoma of the head and neck (ACCHN) incidence and survival trends. (2011) (0)
- Adaptive c-Met-PLXDC2 Signaling Axis Mediates Cancer Stem Cell Plasticity to Confer Radioresistance-associated Aggressiveness in Head and Neck Cancer (2023) (0)
- Head and neck cancer: high-end technology is no guarantee of high-quality care – Authors' reply (2022) (0)
- Defining HPV-specific B cell responses in patients with head and neck cancer (2020) (0)
- Chemoprevention in SCCHN: the Persistent Need for Better Translation (2016) (0)
- Reply, Contralateral irradiation for TlimitedN2bM0 lateralized tonsil cancer (2013) (0)
- Recurrent or metastatic head and neck squamous cell carcinoma that is not responsive to platinum-based chemotherapy progresses very rapidly , and patients have a very poor prognosis , ” (2016) (0)
- CLO23-057: The Influence of Operability Status on Outcomes in Patients With T4a Larynx Cancer: An Institutional Experience (2023) (0)
- Abstract 4257: Predicting fatigue levels of head and neck cancer patients with gene expression using machine learning (2018) (0)
- Effect of the combined treatment with tipifarnib and cetuximab on EGFR and RAS related signaling pathways in H-RAS wild type squamous cell carcinoma of the head and neck (HNSCC) (2020) (0)
- Abstract 1866: HER3 targeting sensitizes HNSCC to cetuximab - evidence from cell line and patient derived xenograft (PDX) models (2016) (0)
- Aneuploidy of anaplastic lymphoma kinase (ALK) gene and association with non squamous lung cancer patient characteristics and outcomes. (2015) (0)
- LOCOREGIONAL THERAPY FOR RESECTABLE OROPHARYNGEAL SQUAMOUS CELL CARCINOMAS (2016) (0)
- Pilot Study of Potential Activation of c-MYC by Aurora Kinase A in Everolimus-Resistant Localized Esophageal Cancer Treated with XELOX followed by Carboplatin/Radiation (2018) (0)
- Comparative features and overall survival in adenosquamous carcinoma, a rare tumor of the esophagus. (2016) (0)
- Impact of Postoperative Radiation Therapy Timing on Survival in HPV-Associated Oropharyngeal Squamous Cell Carcinoma (2020) (0)
- Patient-reported outcomes in immunotherapy for head and neck cancer. (2023) (0)
- Abstract 4387: Total toxicity burden of FDA approved immune checkpoint inhibitors in USA (2023) (0)
- Long-Term Follow-up of Parenteral Bevacizumab In Patients with Recurrent Respiratory Papillomatosis. (2023) (0)
- Abstract 841: Inhibition of head and neck squamous cell carcinoma growth by combination treatment of erlotinib and celecoxib: Potential chemopreventive agents (2011) (0)
- Radiomics in Hypopharyngeal Cancer Management: A State-of-the-Art Review (2023) (0)
- Abstract CT111: Phase 1/2 study of pepinemab, an inhibitor of semaphorin 4D, in combination with pembrolizumab as first-line treatment of recurrent or metastatic head and neck cancer (KEYNOTE B84) (2022) (0)
- Safety and Efficacy of MEDI0457 plus Durvalumab in Patients with Human Papillomavirus–Associated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2022) (0)
- The expanding role of IAP antagonists for the treatment of head and neck cancer. (2023) (0)
- An integrated workflow to identify targetable mutations in FFPE samples of HNSCC. (2016) (0)
- The impact of locoregional recurrence on survival in older patients with differentiated thyroid cancer. (2014) (0)
- Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Cancer. (2023) (0)
- Cancer Therapy : Clinical ChemopreventionofHeadandNeckCancer bySimultaneous Blocking of Epidermal Growth Factor Receptor and Cyclooxygenase-2 Signaling Pathways : Preclinical and Clinical Studies (2013) (0)
- Survival outcomes in extensive stage small cell lung cancer patients treated with thoracic radiation. (2017) (0)
- SALIVARY DUCT CARCINOMA: AN INSTITUTIONAL EXPERIENCE (2016) (0)
- Socioeconomic contributions to clinical outcome by HPV status in squamous cell carcinomas of the head and neck (SCCHN): An analysis of NCDB. (2019) (0)
- Squamous Cell Carcinoma of the Oral Tongue: Exploring New Trends (2014) (0)
- Cervical Lymph Node Metastases from Central Nervous System Tumors: A Systematic Review (2022) (0)
- Heat Shock Protein 90 (HSP90) Is Preferentially Overexpressed in P16-Negative Oropharyngeal Squamous Cell Carcinoma, and its Inhibition In Vitro Potentiates the Effects of Chemoradiation (2014) (0)
- Paranasal sinus squamous cell carcinomas (PNSSCC) incidence and survival trends. (2012) (0)
- 929TiP HERODOTUS: Head and neck cancers international COVID-19 collaboration: An international registry on head and neck cancer with COVID-19 (2021) (0)
- Time to Rethink Our Strategy With a Preoperative Intensification Approach. (2018) (0)
- Novel Immunotherapeutic Approaches to Treating HPV-Related Head and Neck Cancer (2023) (0)
This paper list is powered by the following services:
Other Resources About Nabil F. Saba
What Schools Are Affiliated With Nabil F. Saba?
Nabil F. Saba is affiliated with the following schools:
